Tests a radioactive lead-212 drug in lung and other DLL3-positive neuroendocrine cancers
Tests a radioactive drug targeting DLL3 in adults with small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Key facts
- Where
- Atlanta, Chicago, Cleveland, Glen Burnie, Houston, Omaha, Princeton, and Tampa, United StatesSee the 8 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced small cell lung cancer or other neuroendocrine carcinomas that carry the DLL3 marker. The cancer must have grown or come back after earlier drug treatment.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Advanced small cell lung cancer (extensive or limited stage), large cell neuroendocrine carcinoma of the lung, or neuroendocrine carcinoma outside the lung (gut and pancreas, cervix, bladder, others). The cancer must have grown on scans and have at least one measurable tumour.
- Earlier treatment
- Small cell lung cancer: progression or recurrence after at least two earlier lines of platinum-based drug treatment and immunotherapy, or unable to have or tolerate the standard second-line treatment. Large cell neuroendocrine carcinoma of the lung and cancers outside the lung: progression or recurrence after at least one earlier line of drug treatment. Earlier DLL3-targeted treatment is allowed.
- Biomarker or test result
- For cancers outside the lung, DLL3-positive on a [203Pb]Pb-DOTAM-MAM279 SPECT/CT scan. This scan is also asked for lung cancer patients in Part 2 of the trial. Other cancers outside the lung need DLL3 confirmed earlier by IHC.
Main reasons for not taking part
- Uncontrolled other illness
- Side effects of earlier cancer treatment not yet down to Grade 1 or lower (with some exceptions)
- Active heart disease that matters clinically
- Interstitial lung disease or active non-infectious pneumonitis
- Another cancer in the past 2 years (with some exceptions)
Read by machine on 9 November 2026.
Where in United States
- Emory University HospitalAtlanta, United StatesTaking people
- University of ChicagoChicago, United StatesTaking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
- United TheranosticsGlen Burnie, United StatesTaking people
- The University of Texas MD Anderson Cancer CenterHouston, United StatesTaking people
- Nebraska Cancer SpecialistsOmaha, United StatesTaking people
- United TheranosticsPrinceton, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Molecular Partners AG
- Trial code
- NCT07278479
- Record updated
- 21 October 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.Read full original descriptionShow less
A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Inclusion: Age ≥ 18 years old; Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung; SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy or are not suitable or tolerating the standard of care treatment as second line of systemic therapy, or; LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or recurrence following at least one prior line of systemic therapy:; Gastroenteropancreatic NECs (GEPNEC), or; Cervical NECs, or; Bladder NECs, or; other epNECs with previously confirmed DLL3 expression by IHC; Patients with prior DLL3-targeted therapy are allowed; For epNECs in Part 1 and Part 2 and SCLC or LC NECs of the lung in Part 2: DLL3-positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT; Radiographically documented disease progression or recurrence during or after the last line of systemic treatment therapy; At least one measurable disease per RECIST v1.1; Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening; Adequate blood counts: Hemoglobin ≥9 g/dL; Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L; Platelets ≥100 × 10\^9/L; White blood cells (WBC) ≥2.5 x 10\^9/L; Adequate hepatic function; Adequate renal function: Calculated glomerular filtration rate (GFR) >60mL/min (using Cockroft-Gault formula); Patients with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.
Exclusion: Patients who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for grade ≤2 alopecia, or stable grade 2 sensory neuropathy, according to the last CTCAE version); Uncontrolled intercurrent illness; Active clinically significant cardiac disease; Evidence of interstitial lung disease or active, non-infectious pneumonitis; History of other malignancy within the past 2 years with exceptions; Other protocol-defined inclusion/exclusion criteria may apply.